The board of directors of TigerMed (03347) has passed a resolution to elect Dr. Xiaoping Ye as the Chairman of the sixth board.

His term will commence from the date of the board's approval, June 2, 2026, and will continue until the conclusion of the sixth board's tenure.

The board has also approved the composition of its committees for the sixth term.

The Audit Committee will consist of Mr. Yaoxi Xiao, Mr. Huagang Yuan, and Ms. Yuwen Liu, with Mr. Yaoxi Xiao serving as its chairman.

The Remuneration and Appraisal Committee will be formed by Mr. Huagang Yuan, Mr. Yaoxi Xiao, and Ms. Xiaochun Cao, with Mr. Huagang Yuan as chairman.

The Strategy Committee will comprise Dr. Xiaoping Ye, Mr. Hao Wu, and Mr. Huagang Yuan, led by Dr. Xiaoping Ye as chairman.

The Nomination Committee will include Ms. Yuwen Liu, Mr. Zengyu Wen, and Mr. Yaoxi Xiao, with Ms. Yuwen Liu as chairman.

The terms for all committee members will also begin on June 2, 2026, and last until the end of the sixth board's term.

Additionally, the board has approved several executive appointments.

Mr. Zengyu Wen has been appointed as the company's General Manager, Mr. Hao Wu as Co-President, Mr. Yifei Peng as Chief Operating Officer, and Ms. Chengcheng Yang as Chief Financial Officer.

The board has further resolved to change the company's legal representative from Ms. Xiaochun Cao to Mr. Zengyu Wen.

Other appointments include Ms. Xiaori Li as the Board Secretary and Ms. Xinhui Ruan as the company's Securities Affairs Representative.

Their terms will similarly start on June 2, 2026, and conclude with the sixth board's tenure.